Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Inks Distribution Deal for France

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Asuragen said today that Biomedical Diagnostics (BMD) will distribute its cancer assays in France.

The agreement covers Asuragen's Signature Oncology Portfolio, a line of multiplex assays used to detect mutations in solid and hematologic malignancies. The tests use RT-PCR and multiplex detection using the Luminex 100 or 200 systems.

The portfolio includes a research assay for KRAS and BRAF mutations, an IVD assay that uses RNA from blood or bone marrow to help diagnose certain leukemias, and an assay for simultaneous detection of common NPM1 mutations.

In addition, BMD will support Asuragen's efforts to establish clinical validation sites for the Signature KRAS/BRAF assay in France, Asuragen said.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.